[go: up one dir, main page]

WO2005009384A3 - Egfr tyrosine kinase inhibitors - Google Patents

Egfr tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2005009384A3
WO2005009384A3 PCT/US2004/023662 US2004023662W WO2005009384A3 WO 2005009384 A3 WO2005009384 A3 WO 2005009384A3 US 2004023662 W US2004023662 W US 2004023662W WO 2005009384 A3 WO2005009384 A3 WO 2005009384A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
egfr tyrosine
compounds
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/023662
Other languages
French (fr)
Other versions
WO2005009384A2 (en
Inventor
Yaron Hadari
Leon M Ii Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of WO2005009384A2 publication Critical patent/WO2005009384A2/en
Publication of WO2005009384A3 publication Critical patent/WO2005009384A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention encompasses compounds that inhibit, modulate, or regulate kinases, compositions that contain kinase inhibiting compounds, and methods of treating kinase-dependent diseases and conditions in subjects in need of such treatment. Also, the invention encompasses methods of making compounds that inhibit, modulate or regulate kinases.
PCT/US2004/023662 2003-07-21 2004-07-21 Egfr tyrosine kinase inhibitors Ceased WO2005009384A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48917603P 2003-07-21 2003-07-21
US60/489,176 2003-07-21
US54768204P 2004-02-24 2004-02-24
US60/547,682 2004-02-24

Publications (2)

Publication Number Publication Date
WO2005009384A2 WO2005009384A2 (en) 2005-02-03
WO2005009384A3 true WO2005009384A3 (en) 2005-12-08

Family

ID=34107789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023662 Ceased WO2005009384A2 (en) 2003-07-21 2004-07-21 Egfr tyrosine kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2005009384A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257948A (en) * 2005-02-18 2008-09-03 阿特努奥恩公司 Pyrimidine-fused diazepine derivatives and indole-fused pteridines
CN101679420B (en) * 2007-04-11 2014-05-14 默沙东有限责任公司 A method for preparing enantiomerically pure benzazepine*
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
CN102690278B (en) * 2011-03-21 2015-07-15 长春吉大天元化学技术股份有限公司 Novel pyrimidine-fused cyclic compounds as cytokine inhibitors
CN103509024B (en) * 2012-06-28 2015-10-28 上海医药工业研究院 Kui Linpyrimido quinoline benzazepine compounds and the application as antitumor drug thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU671271A1 (en) * 1977-04-27 1982-10-07 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of pyrimido-(4,5-b) (1,4)-benzoxazepine and process for producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU671271A1 (en) * 1977-04-27 1982-10-07 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of pyrimido-(4,5-b) (1,4)-benzoxazepine and process for producing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEVKOVAKAYA J. ET AL: "Study of Nitrogen- and Oxygen-Containing Heterocycles. 42. Pyrimido[4,5-b]-and pyrido[2,3-b]-1,4-benzoxazepine", KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII, vol. 1, 1985, pages 122 - 125, XP008054762 *
SAFONOVA T.S. ET AL: "Investigation of Nitrogen and Sulfur-Containing Heterocycles. 53* Reactions of 5-Amino-6-Mercapto-Pyrimidines With Derivatives of p-Chloronitrobenzene. Synthesis of a New Heterocyclic System Pyrimido[4,5-b]-1,4-benzothiazepine", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 37, no. 2, February 2001 (2001-02-01), pages 245 - 250, XP002991598 *
SAFONOVA T.S. ET AL: "Synthesis and Biological Properties of Arylthio-1,2,3-triazole Derivatives", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 37, no. 6, June 2003 (2003-06-01), pages 298 - 305, XP002991597 *

Also Published As

Publication number Publication date
WO2005009384A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
WO2005048953A3 (en) Amide derivatives as kinase modulators
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2004089286A3 (en) Novel compounds and compositions as protein kinase inhibitors
AU3113902A (en) Thiazolyl inhibitors of tec family tyrosine kinases
MX2010005950A (en) 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors.
WO2004100947A3 (en) Novel chemical compounds
WO2004073653A3 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
WO2003037252A3 (en) Tyrosine kinase inhibitors
WO2003092595A3 (en) Tyrosine kinase inhibitors
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2002045652A3 (en) Tyrosine kinase inhibitors
WO2006024018A3 (en) Compositions for treating nociceptive pain
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2008066755A3 (en) Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
WO2003015608A3 (en) Combination therapy for the treatment of cancer
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase
WO2003020699A3 (en) Tyrosine kinase inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase